Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Author(s): Aditya Bardia, MD, MPH^1,2; Komal Jhaveri, MD, FACP^3,4; Seock-Ah Im, MD, PhD⁵; Sonia Pernas, MD, PhD⁶; Michelino De Laurentiis, MD⁷; Shusen Wang, MD⁸; Noelia Martínez Jañez, MD, PhD⁹; Giuliano Borges, MD¹⁰; David W. Cescon, MD, PhD¹¹; Masaya Hattori, MD¹²; Yen-Shen Lu, MD, PhD¹³; Erika Hamilton, MD¹⁴; Qingyuan Zhang, MD, PhD¹⁵; Junji Tsurutani, MD, PhD¹⁶; Kevin Kalinsky, MD, MS¹⁷; Pedro Emanuel Rubini Liedke, MD^18,19,20; Lu Xu, PhD²¹; Rick M. Fairhurst, MD, PhD²¹; Sabrina Khan, MD, MPH²¹; Neelima Denduluri, MD²¹; Hope S. Rugo, MD²²; Binghe Xu, MD, PhD²³; Barbara Pistilli, MD²⁴;

Source: https://doi.org/10.1200/JCO.24.00920

Dr. Anjan Patel's Thoughts

Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.

PURPOSE

The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer.

METHODS

Adult patients with inoperable/metastatic HR+/HER2‒ breast cancer, who had disease progression on endocrine therapy, for whom endocrine therapy was unsuitable, and had received one to two previous lines of chemotherapy in the inoperable/metastatic setting, were randomly assigned 1:1 to Dato-DXd (6 mg/kg once every 3 weeks) or ICC (eribulin/vinorelbine/capecitabine/gemcitabine). Dual primary end points were progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS).

RESULTS

Patients were randomly assigned to Dato-DXd (n = 365) or ICC (n = 367). Dato-DXd significantly reduced the risk of progression or death versus ICC (PFS by BICR hazard ratio [HR], 0.63 [95% CI, 0.52 to 0.76]; P < .0001). Consistent PFS benefit was observed across subgroups. Although OS data were not mature, a trend favoring Dato-DXd was observed (HR, 0.84 [95% CI, 0.62 to 1.14]). The rate of grade ≥3 treatment-related adverse events (TRAEs) with Dato-DXd was lower than ICC (20.8% v 44.7%). The most common TRAEs (any grade; grade ≥3) were nausea (51.1%; 1.4%) and stomatitis (50%; 6.4%) with Dato-DXd and neutropenia (grouped term, 42.5%; 30.8%) with ICC.

CONCLUSION

Patients receiving Dato-DXd had statistically significant and clinically meaningful improvement in PFS and a favorable and manageable safety profile, compared with ICC. Results support Dato-DXd as a novel treatment option for patients with inoperable/metastatic HR+/HER2‒ breast cancer who have received one to two previous lines of chemotherapy in this setting.

Author Affiliations

¹Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA; ²Massachusetts General Hospital Cancer Center, Boston, MA; ³Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Weill Cornell Medical College, New York, NY; ⁵Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea; ⁶Institut Català d’Oncologia-IDIBELL, L’Hospitalet, Barcelona, Spain; ⁷Istituto Nazionale Tumori Napoli IRCCS “Fondazione Pascale”, Napoli, Italy; ⁸Cancer Center of Sun Yat-sen University, Guangzhou, China; ⁹Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; ¹⁰Catarina Pesquisa Clínica, Santa Catarina, Brazil; ¹¹Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada; ¹²Aichi Cancer Center, Nagoya, Japan; ¹³National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; ¹⁴Sarah Cannon Research Institute, Nashville, TN; ¹⁵Harbin Medical University Cancer Hospital, Harbin, China; ¹⁶Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan; ¹⁷Winship Cancer Institute at Emory University, Atlanta, GA; ¹⁸Hospital das Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil; ¹⁹UPCO—Pesquisa Clinica em Oncologia, Porto Alegre, Brazil; ²⁰Oncoclinicas Porto Alegre, Porto Alegre, Brazil; ²¹AstraZeneca, Gaithersburg, MD; ²²University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; ²³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ²⁴Gustave Roussy Cancer Center, Villejuif, France;

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial

The WSG-KEYRICHED-1 phase II trial evaluated a chemotherapy-free neoadjuvant regimen of pembrolizumab plus trastuzumab and pertuzumab in HER2-enriched early breast cancer, achieving a pathological complete response (pCR) rate of 46.5% (95% CI 31.2–62.6%). No survival data (e.g., EFS or OS) were reported, but the regimen showed an acceptable safety profile with no new cardiac toxicity signals. The chemo-free approach suggests promising potential for de-escalation in this subtype, but we’ll need randomized trials to confirm its efficacy and safety.

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

The INAVO120 trial assessed inavolisib + palbociclib–fulvestrant vs placebo plus palbociclib–fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, showing significant improvements in progression-free survival (PFS) (15.0 vs 7.3 months) and overall survival (OS) (34.0 vs 27.0 months). The triplet regimen achieved a higher overall response rate (ORR) (62.7% vs 28.0%), establishing it as a potential new standard for this endocrine-resistant population. Notably, side effects like hyperglycemia, stomatitis, diarrhea, and ocular effects were more frequent with inavolisib.

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial

Metronomic dose: low dose cytotoxic therapy at high frequency was studied in combination with an AI (cape at 500mg TID) and showed superiority over AI single agent, this may be an option for patients not tolerating CKD4/6 inhibitors.

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

In summary: It did not work in those patients with stages II-III.

Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial

The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.